Divine Aleru, Microbiome Medicine Research Coordinator

This review explores the role of epithelial barrier dysfunction and microbial dysbiosis in the pathogenesis of Crohn’s disease, highlighting the impact of genetic, environmental, and microbiota factors on disease progression and the potential for therapeutic strategies to restore barrier integrity and balance microbial communities.

This review focuses on the complex pathogenesis of Crohn’s Disease, exploring the roles of microbiome dysbiosis, immune system dysregulation, and environmental factors in disease progression, while highlighting novel therapeutic and diagnostic strategies

This review explores the evolving role of microbiome-targeted therapies in Crohn’s disease, focusing on microbial dysbiosis and its implications for disease progression and treatment.

The study examines the role of microbiome in IBD, highlighting its potential in diagnosing, predicting disease progression, and personalizing treatments.

This study shows women with PCOS have elevated blood lead and cadmium and reduced magnesium, calcium, and manganese—disrupting hormone levels through oxidative stress and possibly altering gut microbiota.

Polycystic ovary syndrome (PCOS) is a common endocrine disorder that affects women of reproductive age, characterized by irregular menstrual cycles, hyperandrogenism, and insulin resistance. It is often associated with metabolic dysfunctions and inflammation, leading to fertility issues and increased risk of type 2 diabetes and cardiovascular disease.

Escherichia coli Nissle 1917 (EcN) is a rare, non-pathogenic strain of E. coli discovered during World War I from a soldier who did not get dysentery while others did. Unlike harmful E. coli, EcN acts as a probiotic: it settles in the gut, competes with bad bacteria for food and space, produces natural antimicrobials, and even helps strengthen the gut barrier.

Ovarian cancer is one of the most lethal cancers affecting women worldwide. Known for its “silent” progression, this disease often goes undetected until it reaches advanced stages, making early diagnosis crucial for improving survival outcomes. With a variety of subtypes, ovarian cancer presents unique challenges in both treatment and prevention. Recent advancements in research are shining a light on the importance of the microbiome, particularly how microbial imbalances in the gut and vaginal microbiota can influence cancer progression. Repurposed drugs such as metformin and innovative interventions like probiotics, microbiota transplantation, and intratumoral microbiota therapies offer promising new avenues for improving ovarian cancer treatment.

This study shows that Escherichia coli Nissle exerts strong dose dependent amebicidal activity against Entamoeba histolytica through oxidative stress and structural damage, highlighting its therapeutic potential.

Escherichia coli Nissle 1917 inhibited Candida albicans growth, reduced virulence traits and protected intestinal cells, showing strong preventive potential through contact based and soluble antifungal mechanisms.

This study shows that Klebsiella pneumoniae L fucose metabolism enhances gut colonization, strengthens biofilm and adherence traits, and increases virulence signalling, identifying a functional metabolic signature relevant to microbiome based clinical risk.

This study shows that the immuno modulatory effect of Escherichia coli Nissle 1917 primes polarized colonic cells, reduces Campylobacter jejuni adhesion and survival, and rebalances NF kappa B, MAPK and Akt signaling to limit inflammation and epithelial injury.

This study shows how Escherichia coli Nissle 1917 inhibitory mechanisms act through adhesion and suppression of EPEC virulence, defining a strong microbiome signature of pathogen interference.

This study shows that Escherichia coli Nissle 1917 microcin MccM is the key factor driving EcN’s inhibition of Salmonella, improving pathogen suppression, reducing cell invasion, and lowering inflammatory cytokine responses.

This study shows that DegP secretion drives probiotic Escherichia coli DegP biofilm inhibition by repressing pathogenic biofilms through a targeted extracellular mechanism that shapes microbial competition.

This study shows how F1C fimbriae in Escherichia coli Nissle 1917 drive biofilm formation, epithelial adhesion, and intestinal persistence, defining a functional microbiome signature for stable colonization.

This review explains how adhesive threads of extraintestinal pathogenic Escherichia coli shape gut colonization, tissue tropism and invasive disease and shows how detailed adhesin profiles can inform microbiome based risk assessment and vaccine design.

This review explores how gut microbiota modulation influences ovarian aging and presents potential therapies like fecal microbiota transplantation and probiotics to prevent or alleviate ovarian aging, offering new strategies for preserving reproductive health.

This review explores the complex role of microbial metabolites in cancer, focusing on their impact on tumor initiation, progression, metastasis, and therapy response. It highlights how microbial products influence the tumor microenvironment and immune modulation, suggesting new avenues for cancer therapy.

This review explores the role of microbiome-derived metabolites in inflammation-related cancer prevention and treatment, highlighting their dual effects in modulating inflammation and immune responses. It discusses key metabolites such as SCFAs, polyamines, and bile acids, along with emerging therapies and the challenges in translating these findings into clinical practice.

This review explores the dual role of gut microbial metabolites in cancer, focusing on their anticancer and pro-carcinogenic effects. It emphasizes the potential of SCFAs, bacteriocins, and dietary modifications in preventing and treating cancer, with a focus on colorectal cancer and other common malignancies.

E. coli Nissle 1917 demonstrates significant antibiofilm activity against P. aeruginosa, inhibiting biofilm formation and dispersing mature biofilms. Its CFS also downregulates key virulence factors and offers protection in a Galleria mellonella model.

This review shows how Salmonella reshapes the gut environment and engages in Salmonella gut infection antagonistic interbacterial interactions with commensals, and it explains how bacteriocins and type six secretion systems shape microbiome signatures and infection risk.

his review shows how siderophore microcins in Escherichia coli support competitive gut colonization, connect the fecal reservoir with urinary tract infection, and define functional microbiome signatures that combine B2 background with microcin, salmochelin and colibactin islands.